• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bydureon 2 mg
    / Astra Zeneca

    Active Ingredient
    Exenatide 2 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Pen

    2 mg X 4 (PEN)

    partial basket chart 11098 16911

    Related information


    The recommended dose is 2 mg exenatide once weekly,for self administration by the patient. Each kit should be used by one person only and is for single use. See prescribing information for full details.


    Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with Metformin,Sulphonylurea,Metformin and sulphonylurea in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.


    Hypersensitivity to the active substance or to any of the excipients.

    Special Precautions

    Must not be administered by intravenous or intramuscular injection. Should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. May cause weight loss, acute pancreatitis.
    See prescribing information for full details.

    Side Effects

    Injection site reactions, Hypoglycaemia, Nausea, Rapid weight loss, patients may develop antibodies to exenatide.
    See prescribing information for full details.


    Effects of overdoses with exenatide (based on exenatide twice daily clinical studies) included severe nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.

    AstraZeneca AB Gärtunavägen Sweden